Clinical Trial Results:
RAPSODY - RANDOMIZED, PROSPECTIVE TRIAL OF TWO SCHEDULES OF SORAFENIB 800 mg DAILY AND INTERFERON ALPHA IN METASTATIC RENAL CELL CARCINOMA MRCC A GOIRC PHASE II STUDY
Summary
|
|
EudraCT number |
2005-005770-72 |
Trial protocol |
IT |
Global completion date |
15 Mar 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
06 Mar 2024
|
First version publication date |
06 Mar 2024
|
Other versions |
|
Summary report(s) |
Could Interferon Still Play a Role in Metastatic Renal Cell Carcinoma? A Randomized Study of Two Schedules of Sorafenib Plus Interferon-Alpha 2a (RAPSODY) |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.